logo

APYX

Apyx Medical·NASDAQ
--
--(--)
--
--(--)
0.48 / 10
Underperform

Fundamental quality is subpar (0.5/10). Key weaknesses include negative Net income-Revenue (-0.1668) and Cash-MV (-0.0673) factors, a low ROA (-16.14%), and an Asset-MV deficit (-0.5007). Only Cash-UP (+) and Net profit attributable to parent company shareholders / Net profit ratio are favorable. Historical back-tests show consistently negative short-term returns for most factors, reinforcing the underperform stance.

Fundamental(0.48)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.24
Score3/3
Weight-165.90%
1M Return7.09%
ROA (%)
Value-16.14
Score2/3
Weight5.80%
1M Return-0.39%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.48
Score2/3
Weight25.18%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight35.55%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight61.39%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-21.53
Score2/3
Weight5.80%
1M Return-0.39%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight28.39%
1M Return-1.95%
Asset-MV
Value-0.50
Score1/3
Weight9.90%
1M Return-0.63%
Cash-MV
Value-0.07
Score1/3
Weight67.44%
1M Return-5.64%
Net profit / Total profit (%)
Value101.82
Score2/3
Weight26.44%
1M Return-1.71%
Is APYX fundamentally strong?
  • APYX scores 0.48/10 on fundamentals and holds a Premium valuation at present. Backed by its -97.11% ROE, -30.32% net margin, -10.95 P/E ratio, 26.18 P/B ratio, and 56.10% earnings growth, these metrics solidify its Underperform investment rating.